All Articles

Darigold's partnership with Actus Nutrition isn't a retreat, but a strategic masterstroke redefining the value of milk in a high-tech protein market.

Ahead of its token launch, nGRND has drawn 855k gamers with a novel promise: rewards backed by preserved, unmined gold. Is this the future of Web3?

A new study on couples' supplements shows impressive well-being gains, but a closer look at the methodology reveals a gap between marketing and hard science.

TELUS's #StandWithOwners returns, but its new focus on a year-round community reveals a deeper strategy: building an ecosystem, not just running a contest.

A new grant program for police tech seems simple, but Veritone's partnership with Police1 is a shrewd move to overcome the biggest sales hurdle: budget.

As Recursion heads to a key investor conference, it must prove its AI-powered drug discovery platform can deliver financial results, not just scientific promise.

AI is moving from the cloud to the world around us. New, powerful hardware is making our cities and industries smarter, but it demands a new level of trust.

Co-Diagnostics is developing a point-of-care Ebola test promising 30-minute results. But can it navigate regulatory hurdles and reach the front lines in time?

The 'better-for-you' brand is betting on a booming peanut butter market with its first non-chocolate snack, a strategic move backed by deep market data.

Upcoming study results for Bayer's KERENDIA could unlock a new treatment for millions with non-diabetic chronic kidney disease, a vast and underserved group.

With the appointment of Roku and Viant veteran Tom Wolfe, Locality signals a major play to solve local TV's biggest challenges: fragmentation and opacity.

JFrog's inclusion in the Russell 3000 isn't just a corporate win; it's a signal of the market's new respect for the software supply chain's vital role.

Despite massive security investments, known vulnerabilities are wreaking havoc. A new report reveals why AI demands a shift from pre-production to runtime defense.

As Motorcar Parts of America preps its FY2026 report, investors await answers on declining revenue and the strategic review of its once-touted EV business.

A Canadian firm is betting big on natural hydrogen, a clean energy source found underground. With new funding and political clout, is this the future?

Inipharm's INI-822 study leverages genetic insights for an oral MASH therapy, challenging injectable rivals and offering new hope for high-risk patients.

With real estate worth more than its stock and ambitious R&D plans, Cosmos Health claims it's undervalued. But is an unusual crypto strategy clouding the picture?

An analysis of 89 school districts reveals a new data-driven playbook for reducing chronic absenteeism, with major implications for EdTech and human capital.

Frazier Healthcare Partners adds Milton Boyer as an EIR, signaling a strategic push into the complex pharmaceutical manufacturing sector with a proven operator.

Neil Jesani Advisors' high-profile board appointments reveal a new playbook for growth, where political savvy and tech innovation are the ultimate currency.